Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: Progress and challenges

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 7, 2008, Pages 883-903

  Rokosz, Laura L ^a   Beasley, James R ^a   Caroll, Carolyn Dilanni ^a   Lin, Tsung ^a   Zhao, Jiuqiao ^a   Appell, Kenneth C ^a   Webb, Maria L ^a  

^a PHARMACOPEIA INC   (United States)

Author keywords

Autoimmune disease; Bruton's tyrosine kinase; BTK; Chain; Common ; Cytokines; Delayed type hypersensitivity; Dry eye; DTH; Inflammation; IRAK 4; JAK 3; Janus kinase; p38; PKC ; Psoriasis; Rheumatoid arthritis; Rho kinase; SCID; Severe combined immunodeficiency; Signal transducers and activators of transcription; STAT; TYK; Tyrosine kinase c; X linked agammaglobulinemia; X linked immunodeficiency; XID; XLA

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; AMG 548; BMS 582949; BRUTON TYROSINE KINASE INHIBITOR; CYCLOSPORIN; DASATINIB; DORAMAPIMOD; FASUDIL; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4 INHIBITOR; JANUS KINASE 3 INHIBITOR; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NVP AEB 071; PH 797804; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PROTEIN KINASE C THETA INHIBITOR; PROTEIN KINASE INHIBITOR; PS 020613; PS 166276; RAPAMYCIN; RHO KINASE INHIBITOR; RO 320 1195; SB 681323; TACROLIMUS; UNINDEXED DRUG; VX 702;

ANEMIA; ATHEROSCLEROSIS; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC INFLAMMATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; IMMUNOBIOLOGY; IMMUNOPATHOLOGY; INFECTION; INNATE IMMUNITY; KIDNEY GRAFT REJECTION; MONOTHERAPY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PSORIASIS; RAYNAUD PHENOMENON; REVIEW; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY; SIDE EFFECT;

ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 48949116929     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.7.883     Document Type: Review

References (140)

1. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-30
2. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83
3. Raingeaud J, Whitmarsh AJ, Barrett T, et al. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 1996;16:1247-55
4. Allen M, Svensson L, Roach M, et al. Deficiency of the stress kinase p38α results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med 2000;191:859-70
5. Adams JL, Badger AM, Kumar S, et al. p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. Prog Med Chem 2001;38:1-60
6. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46
7. Henry JR, Cavender DE, Wadsworth SA. p38 Mitogen-activated protein kinase as a target for drug discovery. Drugs Future 1999;24:1345-54
8. Salituro FG, Germann UA, Wilson KP, et al. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr Med Chem 1999;6:807-23
9. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71
10. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-66
11. Cvetkovic RS, Keating G. Anakinra. Bio Drugs 2002;16:303-11
12. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-26
13. Kumar S, McDonnell PC, Gum RJ, et al. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 1997;235:533-8
14. McLay LM, Halley F, Souness JE, et al. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg Med Chem 2001;9:537-54
15. Natarajan SR, Wisnoski DD, Singh SB, et al. p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold. Bioorg Med Chem Lett 2003;13:273-6
16. Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;9:268-72
17. Wadsworth SA, Cavender DE, Beers SA, et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999;291:680-7
18. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat Cell Biol 1999; 1:94-7
19. Lin TH, Metzger A, Diller DJ, et al. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors. J Pharmacol Exp Ther 2006;318:495-502
20. Godl K, Wissing J, Kurtenbach A, et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 2003;100:15434-9
21. Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36
22. Diller DJ, Lin TH, Metzger A. The discovery of novel chemotypes of p38 kinase inhibitors. Curr Top Med Chem 2005;5:953-65
23. Chen M, Cheng A, Candotti F, et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol 2000;20:947-56
24. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000;20:3387-95
25. Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995;377:65-8
26. Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995;270:797-800
27. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-8
28. Kudlacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004;4:51-7
29. Milici AJ, Audoly L, Beckius GE, et al. Cartilage preservation by inhibition of Janus kinase 3 (JAK3) in a murine collagen induced-arthritis (CIA) model and rat adjuvant-arthritis (AA) model. American College of Rheumatology 70th Annual Meeting; 2006; Washington, DC; 2006. Presentation number 789. Availabel from: http://www.abstractsonline.com/ viewer/?mkey=%7BC297FAF7% 2D2B4C%2D45F5%2DA662%2D0972E 559ED7D%7D%20
30. Busque S, Leventhal J, Brennan D, et al. CP-690,550 (CP), a JAK3 inhibitor, in de novo kidney transplant (KT) recipients: 6-month results of a phase 2 trial [abstract 601]. Am J Transpl 2007;7(s2):304
31. Sudbeck EA, Liu XP, Narla RK, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptasis-inducing antileukemic agents. Clin Cancer Res 1999;5:1569-82
32. Kirken RA, Erwin RA, Taub D, et al. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol 1999;65:891-9
33. Stepkowski SM, Erwin-Cohen RA, Behbod F, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002;99:680-9
34. Stepkowski SM, Kao J, Wang ME, et al. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol 2005;175:4236-46
35. Cortes JR, Perez GM, Rivas MD, et al. Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. J Immunol 2007;179:3881-7
36. Sills M, Appell K, Bohnstedt A, et al. In vitro and in vivo characterization of a novel Jak3 tyrosine kinase inhibitor. Inflamm Res 2006;55:S118
37. Chang B, Zhao F, Lau A, et al. Novel Jak kinase inhibitors reverse inflammation and bone erosion in a collagen-induced arthritis (CIA) treatment model: PKIPD evaluation using phospho-flow cytometry. Program of Keystone Symposia: Jaks, Stats and Immunity; 2007; Steamboat Springs, CO, USA (Abstract 111)
38. Hendry S, Sheikh A, Bogt K, et al. Prevention of acute rejection with a novel Janus kinase 3 (JAK-3) inhibitor in a rodent heterotopic cardiac allograft model. World Transplantation Congress; 2006; Boston, MA USA. Am J Transpl 2006;6(Suppl 2):901
39. Deuse T VJ, Hoyt G, Govaert JA, et al. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation 2008;85:885-92
40. Chan G, Wang C, Boy M, et al. Dose-dependent reduction in psoriasis severity as evidence of immunosuppressive activity of an oral JAK3 inhibitor in humans. Am J Transpl 2006;6(Suppl 2):87
41. Kremer J, Bloom B, Breedveld F. A randomized, double-blind placebo-controlled trial of 3 dose levels of CP-690, 550 versus placebo in the treatment of active rheumatoid arthritis [abstract L40]. American College of Rheumatology 70th Annual Meeting; 2006; Washington, DC
42. Rubins A, Gutmane R, Valdmane N, et al. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol 2005;125:68-71
43. Goodman PA, Wood CM, Vassilev AO, et al. Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia. Leuk Lymphoma 2003;44:1011-8
44. Vassilev AO, Uckun FM. Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK). Curr Pharm Des 2004;10:1757-66
45. Rawlings DJ, Scharenberg AM, Park H, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 1996;271:822-5
46. Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361:226-33
47. Khan WN. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol Res 2001;23:147-56
48. Ohta Y, Haire RN, Litman RT, et al. Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia. Proc Natl Acad Sci USA 1994;91:9062-6
49. Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993;261:358-61
50. Sideras P, Muller S, Shiels H, et al. Genomic organization of mouse and human Bruton's agammaglobulinemia tyrosine kinase (Btk) loci. J Immunol 1994;153:5607-17
51. Lindvall JM, Blomberg KE, Valiaho J, et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 2005;203:200-15
52. Watanabe D, Hashimoto S, Ishiai M, et al. Four tyrosine residues in phospholipase C-γ2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling. J Biol Chem 2001;276:38595-601
53. Uckun FM. Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem Pharmacol 1998;56:683-91
54. Horwood NJ, Mabon T, McDaid JP, et al. Bruton's tyrosine kinase is required For lipopolysaccharide-induced tumor necrosis factor α production. J Exp Med 2003;197:1603-11
55. Horwood NJ, Page TH, McDaid JP, et al. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol 2006;176:3635-41
56. Mangla A, Khare A, Vineeth V, et al. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood 2004;104:1191-7
57. Cohen SB, Emery P, Greenwald MW, et al. Rituximab far rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
58. Hata D, Kawakami Y, Inagaki N, et al. Involvement of Bruton's tyrosine kinase in FcṘI-dependent mast cell degranulation and cytokine production. J Exp Med 1998;187:1235-47
59. Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007;104:13283-8
60. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem Med Chem 2007;2:58-61
61. Mahajan S, Ghosh S, Sudbeck EA, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-AI3 [α-cyano-β-hydroxy-β-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem 1999;274:9587-99
62. Uckun FM, Zheng Y, Cetkovic-Cvrlje M, et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) prapenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res 2002;8:1224-33
63. Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett 2002;527:274-8
64. Cetkovic-Cvrlje M, Uckun FM. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br J Haematol 2004;126:821-7
65. Uckun FM, Vassilev A, Bastell S, et al. The anti-leukemic Bruton's tyrosine kinase inhibitor α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism. Leuk Lymphoma 2003; 44:1569-77
66. Kawakami Y, Hartman SE, Kinoshita E, et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. Proc Natl Acad Sci USA 1999;96:2227-32
67. Basu S, Bose SK Jr, Bose SK. Characterization of versilin-sensitive sites in self-sensitive producer and sensitive non-producer or unrelated organism. J Appl Bacteriol 1989;67:191-200
68. Osada S, Mizuno K, Saido TC, et al. A new member of the protein kinase C family, nPKCθ, predominantly expressed in skeletal muscle. Mol Cell Biol 1992;12:3930-8
69. Chang JD, Xu Y, Raychowdhury MK, et al. Molecular cloning and expression of a eDNA encoding a novel isoenzyme of protein kinase C (nPKC). A new member of the nPKC family expressed in skeletal muscle, megakaryoblastic cells, and platelets. J Biol Chem 1993;268:14208-14
70. Hayashi K, Altman A. Protein kinase C theta (PKCθ): a key player in T cell life and death. Pharmacol Res 2007;55:537-44
71. Sedwick CE, Altman A. Perspectives on PKCθ in T cell activation. Mol Immunol 2004;41:675-86
72. Sun Z, Atendt CW, Ellmeier W, et al. PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes. Nature 2000;404:402-7
73. Pfeifhofer C, Kofler K, Gruber T, et al. Protein kinase C θ affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J Exp Med 2003;197:1525-35
74. Anderson K, Fitzgerald M, Dupont M, et al. Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases. Autoimmunity 2006;39:469-78
75. Salek-Ardakani S, So T, Halteman BS, et al. Protein kinase Cθ controls Th1 cells in experimental autoimmune encephalomyelitis. J Immunol 2005;175:7635-41
76. Tan SL. PKCθ: a potential therapeutic target for multiple sclerosis. Presented at the 4th Annual Protein Kinase Targets conference; 2006 June 12-14, Boston, MA, USA
77. Healy AM, Izmailova E, Fitzgerald M, et al. PKC-θ-deficient mice are protected from Th1-dependent antigen-induced arthritis. J Immunol 2006;177:1886-93
78. Marsland BJ, Soos TJ, Spath G, et al. Protein kinase C θ is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses. J Exp Med 2004;200:181-9
79. Salek-Ardakani S, So T, Halteman BS, et al. Differential regulation of Th2 and Th1 lung inflammatory responses by protein kinase Cθ. J Immunol 2004;173:6440-7
80. Berg-Brown NN, Gronski MA, Jones RG, et al. PKCθ signals activation versus tolerance in vivo. J Exp Med 2004;199:743-52
81. Giannoni F, Lyon AB, Wareing MD, et al. Protein kinase C θ is not essential for T-cell-mediated clearance of murine gammaherpesvirus 68. J Virol 2005;79:6808-13
82. van Eis MJ. NVP-AEB071: first protein kinase c inhibitor prolonging graft survival in a transplantation model. XIXth International Symposium on Medicinal Chemistry; 2006 August 29 - September 2, Istanbul, Turkey
83. Slade A, Jung T, Hijazi Y, et al. AEB071: safety and activity of a novel T-cell activation inhibitor in psoriasis patients. 2007
84. Cywin CL, Dahmann G, Prokopowicz AS 3rd, et al. Discovery of potent and selective PKC-θ inhibitors. Bioorg Med Chem Lett 2007;17:225-30
85. Leitges M, Plomann M, Standaert ML, et al. Knockout of PKCα enhances insulin signaling through PI3K. Mol Endocrinol 2002;16:847-58
86. -/- mice. J Immunol 2006;176:6004-11
87. Mecklenbrauker I, Saijo K, Zheng NY, et al. Protein kinase Cδ controls self-antigen-induced B-cell tolerance. Nature 2002;416:860-5
88. Miyamoto A, Nakayama K, Imaki H, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ. Nature 2002;416:865-9
89. Janssens S, Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 2003;11:293-302
90. Kuglstatter A, Villasenor AG, Shaw D, et al. Cutting Edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations. J Immunol 2007;178:2641-5
91. Wang Z, Liu J, Sudom A, et al. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Structure 2006;14:1835-44
92. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511
93. O'Neill LA. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 2003;3:396-403
94. Li S, Strelow A, Fontana EJ, et al. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA 2002;99:5567-72
95. Yao J, Kim TW, Qin J, et al. Interleukin-1 (IL-1)-induced TAK1-dependent Versus MEKK3-dependent NFκB activation pathways bifurcate at IL-1 receptor-associated kinase modification. J Biol Chem 2007;282:6075-89
96. Suzuki N, Suzuki S, Duncan GS, et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 2002;416:750-6
97. Qin J, Jiang Z, Qian Y, et al. IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness. J Biol Chem 2004;279:26748-53
98. Lye E, Mirtsos C, Suzuki N, et al. The role of interleukin 1 receptor-associated kinase-4 (IRAK-4) kinase activity in IRAK-4-mediated signaling. J Biol Chem 2004;279:40653-8
99. Kim TW, Staschek K, Bulek K, et al. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J Exp Med 2007;204:1025-36
100. Kawagoe T, Sato S, Jung A, et al. Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling. J Exp Med 2007;204:1013-24
101. Koziczak-Holbro M, Joyce C, Gluck A, et al. IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and toll-like receptor 7-mediated signaling and gene expression. J Biol Chem 2007;282:13552-60
102. Suzuki N, Suzuki S, Millar DG, et al. A critical role for the innate immune signaling molecule IRAK-4 in T cell activation. Science 2006;311:1927-32
103. Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003;299:2076-9
104. Medvedev AE, Lentschat A, Kuhns DB, et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 2003;198:521-31
105. Ku CL, von Bermuth H, Picard C, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007;204:2407-22
106. Smith RJ. Therapies for rheumatoid arthritis: hope springs eternal. Drug Discov Today 2005;10:1598-606
107. Fernandes LB, Henry PJ, Galdie RG. Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis 2007;1:25-33
108. Hu E, Lee D. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. Expert Opin Ther Targets 2005;9:715-36
109. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98:322-34
110. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 200 5;4:387-98
111. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003;4:446-56
112. Seasholtz TM, Brown JH. Rho signaling in vascular diseases. Mol Interv 2004;4:348-57
113. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007;28:296-302
114. Xing XQ, Gan Y, Wu SJ, et al. Therapeutic potential of Rho-kinase inhibitors in asthma. Med Hypotheses 2007;68:705-6
115. Chiba Y, Ueno A, Shinozaki K, et al. Involvement of RhoA-mediated Ca2+ sensitization in antigen-induced bronchial smooth muscle hyperresponsiveness in mice. Respir Res 2005;6:4-15
116. Gosens R, Schaafsma D, Grootte Bromhaar MM, et al. Growth factor-induced contraction of human bronchial smooth muscle is Rho-kinase-dependent. Eur J Pharmacol 2004;494:73-6
117. Henry PJ, Mann TS, Goldie RG. A rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice. Pulm Pharmacol Ther 2005;18:67-74
118. Urata Y, Nishimura Y, Hirase T, et al. Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase. Kabe J Med Sci 2005;51:17-27
119. Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Bio Drugs 2007;21:167-77
120. Uehata M, Ishizaki T, Satah H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-4
121. Stavenger R. Rho kinase inhibitors as potential therapeutic agents for cardiovascular disease. Gordon Conference an Medicinal Chemistry; 2007; New London, NH: GlaxoSmithKline
122. Ishikawa Y, Nishikimi T, Akimoto K, et al. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 2006;47:1075-83
123. Nishikimi T, Matsuoka H. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis. J Pharmacol Sci 2006;100:22-8
124. Nakagawa O, Fujisawa K, Ishizaki T, et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996;392:189-93
125. Leung T, Chen XQ, Manser E, et al. The p160 RhoA-binding kinase ROKα is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996;16:5313-27
126. Riento K, Totty N, Villalonga P, et al. RhoE function is regulated by ROCK-I mediated phosphorylation. EMBO J 2005;24:1170-80
127. Shimizu Y, Thumkeo D, Keel J, et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 2005;168:941-53
128. Thumkeo D, Keel J, Ishizaki T, et al. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 2003;23:5043-55
129. Ellis J, Kuo J, McGonigle S, et al. Ability of the ROCK-2 selective inhibitor SLx-2119 to inhibit septic liver injury [abstract FC11.7]. 8th World Congress on Inflammation; 2007 June 16 - 20; Copenhagen Conference Center, Bella Center, Copenhagen, Denmark. Inflamm Res 2007;56(Suppl 3):S403
130. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rha-kinase-involved pathway. Pharmacol Ther 2002;93:225-32
131. Tamura M, Nakao H, Yoshizaki H, et al. Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta 2005;1754:245-52
132. Lindsley C, Zhao Z, Leister W, et al. Allosteric AKT (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 2005;761-4
133. Available from: http://www.scientific.thomson.com
134. Creager MA. The effect of fasudil on vascular function in humans. 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00120718 [Last accessed 10 December 2007]
135. Wigley FD. A rho-kinase inhibitor (Fasudil) in the treatment of Raynaud's phenomenon. 2007. Available from: http://clinicaltrials.gov/ show/NCT00498615 [Last accessed 10 December 2007]
136. Mitsubishi Tanabe Pharma pipeline. 2008. Available from http://www.evaluatepharma.com/CoInfo/CoInfo-TAN.htm [Last accessed 5 May 2008]
137. KOWA Pharmaceuticals pipeline. 2007. Available from: http://www.kowa.co.jp/eng/g/rd/pipeline.htm [Last accessed 5 May 2008]
138. Santen Annual Report 2007. Santen Pharmaceutical Co, Ltd Annual Report 2007. 2007. Available from: http://www.santen.com/ir/reports/ar2007.jsp [Last accessed 5 May 2008]
139. Branca MA, Sannes L. Multi-target kinase inhibitors hitting the market. PharmaWeek. 2006 March 24. Available from: http://www.pharmaweek.com/ 6FlashReport/MultiTarget%20Kinase.asp [Last accessed 9 May 2008]
140. Zheng C, Han L, Yap C, et al. Progress and problems in the exploration of therapeutic targets. Drug Discov Today 2006;11:412-20